Holen Sie sich die Stockscreener-App
270.15
2.84%
7.47
Handel nachbörslich:
270.66
0.51
+0.19%
Schlusskurs vom Vortag:
$262.68
Offen:
$270.2
24-Stunden-Volumen:
365.00K
Relative Volume:
1.53
Marktkapitalisierung:
$28.03B
Einnahmen:
$5.76B
Nettoeinkommen (Verlust:
$514.49M
KGV:
60.28
EPS:
4.4813
Netto-Cashflow:
$1.10B
1W Leistung:
+3.80%
1M Leistung:
-7.83%
6M Leistung:
-12.01%
1J Leistung:
+6.87%
1-Tages-Spanne:
$265.02
$274.55
1-Wochen-Bereich:
$259.09
$274.55
52-Wochen-Spanne:
$239.25
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
270.15 | 27.25B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Barclays | Overweight |
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
Barings LLC Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Here's How Much You Would Have Made Owning BeOne Medicines Stock In The Last 10 Years - Sahm
A Look At BeOne Medicines (ONC) Valuation After Analyst Upgrades And Positive ASCO 2026 Clinical Updates - Sahm
Capital International Sarl Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Ltd.Sponsored ADR $ONC Position Raised by Capital International Investors - MarketBeat
Is BeOne Medicines (ONC) Quietly Recasting Its Hematology Roots Into a Multi-Franchise Oncology Platform? - Sahm
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 - sharewise.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Range Breakout - AASTOCKS.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Triangle Breakout - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 5.1M shares at $176.8, $901.68M turnover - AASTOCKS.com
BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 254.9K shares at $175.1, $44.633M turnover - AASTOCKS.com
CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK) - AASTOCKS.com
Marriott Upgraded, Roku Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Bearish block trade of BEONE MEDICINES(06160) 231.3K shares at $185.8, $42.976M turnover - AASTOCKS.com
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative - Sahm
HSI To Add J&T EXPRESS-W (01519.HK), CHALCO (02600.HK), BEONE MEDICINES (06160.HK) after Quarterly Review - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 212K shares at $184.5, $39.114M turnover - AASTOCKS.com
ONC Stock Price, Quote & Chart | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Ltd.: BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - FinanzNachrichten.de
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Via TT
Bearish block trade of BEONE MEDICINES(06160) 323.6K shares at $183.1, $59.251M turnover - AASTOCKS.com
BeOne Medicines Wins FDA Nod For BEQALZI In Mantle Cell Lymphoma - Sahm
Bearish block trade of BEONE MEDICINES(06160) 206.1K shares at $175.1, $36.088M turnover - AASTOCKS.com
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer - Sahm
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - ChartMill
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Apple Upgraded, American Express Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BeOne Medicines (ONC) Is Up 7.4% After Guidance Hike And Priority Review Win In HER2 Cancer - Sahm
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
UBS Group AG Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BOCI: BEONE MEDICINES 1Q Results Beat; Rating Buy Reiterated - AASTOCKS.com
G Sachs Raises BeOne Medicines Ltd. (ONC.US) TP to USD414.46, Rating Buy - AASTOCKS.com
UBS Raises BeOne Medicines Ltd. (ONC.US) TP to USD465, 1Q Results Strong - AASTOCKS.com
M Stanley Raises BeOne Medicines Ltd. (ONC.US) TP to USD395; 1Q Results Beat Expectations - AASTOCKS.com
BeOne Medicines Q1 Earnings Call Highlights - Yahoo Finance
BeOne Medicines (ONC) registers 398.9M ordinary shares for resale by major holders - Stock Titan
BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance - AASTOCKS.com
Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain? - Sahm
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Sahm
BeOne Medicines files 2025 annual report with Shanghai STAR Market - Investing.com
Oil Shock, AI Tailwinds, And Portfolio Shifts Across Emerging Markets - Seeking Alpha
Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Is BeOne (ONC) Stock entering maturity stage | ONC Q4 2025 Earnings: BeOne Medicines Ltd. ADS misses EPS, no revenue releasedADR - Newser
RBC Capital Adjusts Price Target on BeOne Medicines to $423 From $425, Maintains Outperform Rating - Moomoo
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.50%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):